Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin

Drug Res (Stuttg). 2015 Nov:65 Suppl 1:S13. doi: 10.1055/s-0035-1558063. Epub 2015 Nov 4.
No abstract available

MeSH terms

  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use*
  • Drug Design
  • Fibroblast Growth Factors / pharmacology
  • Fibroblast Growth Factors / therapeutic use*
  • Humans
  • Middle Aged
  • Osteoarthritis, Knee / drug therapy*
  • Osteoarthritis, Knee / epidemiology
  • Osteoarthritis, Knee / pathology

Substances

  • Antirheumatic Agents
  • fibroblast growth factor 18
  • Fibroblast Growth Factors